grain0612
2021-04-23T16:46:00+00:00
[url]https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-urges-china-to-clear-bottlenecks-on-key-pharma-raw-material/articleshow/82308731.cms[/url]
India urges China to clear bottlenecks on key pharma raw-material
印度药品出口促进机构印度药品出口促进委员会(Pharmexcil)周四呼吁印度驻中国大使馆立即干预，以消除由于严重的供应链中断而从中国进口关键原料的瓶颈。
在中国国有航空公司四川航空公司决定在第二次Covid浪潮之后将其向印度的货运服务暂停15天的决定的背景下，Pharmexcil总干事Ravi Uday Bhaskar写信给印度驻中国大使Vikram Misri立即干预-19。
Pharmexcil担心，中国航空公司的决定将对整个供应链产生连锁反应，导致基本药物短缺，不仅满足印度的国内需求，而且对印度出口满足全球需求的药品产生不利影响。大流行病。
到2021年3月，印度散装毒品和中间体的进口总额为38.4亿美元，其中26亿美元(占散装毒品和中间体的68%)从中国进口。
乌代·巴斯卡(Uday Bhaskar)向印度大使米斯里(Misri)表示，印度目前正在从中国采购其60%至70%的药物中间体，关键起始原料(KSM)和活性药物成分(API)需求。此外，“最重要的是所有API的45-50%
Pharmexcil总干事说。
Uday Bhaskar说，尽管印度政府已经针对API制造推出了产品链接激励(PLI)计划，但“要减少我们对进口KSM的依赖将需要一些时间。”
Pharmexcil的高管表示，即使在Covid第二波艰难时期，印度制药业仍在努力履行全球承诺，“中国国有四川航空公司做出的在15天内暂停向印度提供货运服务的决定令人担忧。除了运费增加和集装箱短缺之外。”
乌代·巴斯卡(Uday Bhaskar)表示，华航的决定“可能会破坏印度制药业为进口医疗用品而进行的疯狂努力，其中包括制造浓缩制剂所需的氧气浓缩器以及KSM / API。该行业担心对整个供应链的连锁影响，导致该国人口所需的基本药物短缺以及对出口的严重影响。”
Pharmexcil总干事呼吁印度大使“采取干预措施，并采取必要措施，通过恢复四川航空公司的货运服务或安排印度航空货运来恢复包括KSM / APIs等在内的我国医疗需求的供应链。提起医疗用品。”
Pharmaceuticals Export Promotion Council of India (Pharmexcil), the country’s nodal agency for exports of pharmaceuticals, on Thursday appealed to the Indian Ambassador in China to immediately intervene in clearing bottlenecks on import of key raw materials from China amid serious supply chain disruptions.
The Pharmexcil director-general Ravi Uday Bhaskar wrote to Indian Ambassador in China Vikram Misri for an immediate intervention in the backdrop of the decision of the Chinese state-owned Sichuan Airlines to suspend its cargo services to India for 15 days following the second wave of Covid-19.
Pharmexcil fears that the decision of the Chinese airlines would have cascading effects on the entire supply chain, leading to a shortage of essential medicines for not just for India’s domestic needs but also adversely affect its pharmaceutical exports to meet the global needs in the time of the pandemic.
India's overall imports of bulk drugs and drug intermediates amounted to $3.84 billion in fiscal to March 2021. Of this, $2.6 billion or 68% of bulk drugs and intermediates are imported from China.
Uday Bhaskar submitted to the Indian Ambassador Misri that India is currently sourcing 60-70% of its requirement of drug intermediates, key starting material (KSMs) and active pharmaceutical ingredients (APIs) from China. Further, “most importantly 45-50% of all APIs
imported feature in the National List of Essential Medicines (NLEM),” said the Pharmexcil director-general.
Though the Indian government had rolled out the Product Linked Incentive (PLI) scheme for API manufacturing, “it is going to take some time to reduce our dependency on import of KSMs,” said Uday Bhaskar.
The Pharmexcil top executive said even as the Indian pharmaceutical sector was struggling hard to meet the global commitments during the hard phase of Covid second wave, “the decision of Chinese state-owned Sichuan Airlines suspending its cargo services to India for 15 days is worrisome in addition to increased freight cost and shortage of containers.”
Uday Bhaskar said the decision of Chinese Airlines “is likely to disrupt frantic efforts by Indian pharma industry to import medical supplies including oxygen concentrators as well as the KSMs/APIs required to manufacture finished formulations. The Industry is fearing of cascading effects on its entire supply chain leading to a shortage of the essential medicines for the nation’s population as well as severe impact on exports.”
The Pharmexcil director-general appealed to the Indian Ambassador “to intervene and take necessary measures to restore the supply chain of medical needs of our country including KSMs/APIs etc either by restoring the cargo services of Sichuan Airlines or by way of arranging Indian air cargo to lift the medical supplies.”
India urges China to clear bottlenecks on key pharma raw-material
印度药品出口促进机构印度药品出口促进委员会(Pharmexcil)周四呼吁印度驻中国大使馆立即干预，以消除由于严重的供应链中断而从中国进口关键原料的瓶颈。
在中国国有航空公司四川航空公司决定在第二次Covid浪潮之后将其向印度的货运服务暂停15天的决定的背景下，Pharmexcil总干事Ravi Uday Bhaskar写信给印度驻中国大使Vikram Misri立即干预-19。
Pharmexcil担心，中国航空公司的决定将对整个供应链产生连锁反应，导致基本药物短缺，不仅满足印度的国内需求，而且对印度出口满足全球需求的药品产生不利影响。大流行病。
到2021年3月，印度散装毒品和中间体的进口总额为38.4亿美元，其中26亿美元(占散装毒品和中间体的68%)从中国进口。
乌代·巴斯卡(Uday Bhaskar)向印度大使米斯里(Misri)表示，印度目前正在从中国采购其60%至70%的药物中间体，关键起始原料(KSM)和活性药物成分(API)需求。此外，“最重要的是所有API的45-50%
Pharmexcil总干事说。
Uday Bhaskar说，尽管印度政府已经针对API制造推出了产品链接激励(PLI)计划，但“要减少我们对进口KSM的依赖将需要一些时间。”
Pharmexcil的高管表示，即使在Covid第二波艰难时期，印度制药业仍在努力履行全球承诺，“中国国有四川航空公司做出的在15天内暂停向印度提供货运服务的决定令人担忧。除了运费增加和集装箱短缺之外。”
乌代·巴斯卡(Uday Bhaskar)表示，华航的决定“可能会破坏印度制药业为进口医疗用品而进行的疯狂努力，其中包括制造浓缩制剂所需的氧气浓缩器以及KSM / API。该行业担心对整个供应链的连锁影响，导致该国人口所需的基本药物短缺以及对出口的严重影响。”
Pharmexcil总干事呼吁印度大使“采取干预措施，并采取必要措施，通过恢复四川航空公司的货运服务或安排印度航空货运来恢复包括KSM / APIs等在内的我国医疗需求的供应链。提起医疗用品。”
Pharmaceuticals Export Promotion Council of India (Pharmexcil), the country’s nodal agency for exports of pharmaceuticals, on Thursday appealed to the Indian Ambassador in China to immediately intervene in clearing bottlenecks on import of key raw materials from China amid serious supply chain disruptions.
The Pharmexcil director-general Ravi Uday Bhaskar wrote to Indian Ambassador in China Vikram Misri for an immediate intervention in the backdrop of the decision of the Chinese state-owned Sichuan Airlines to suspend its cargo services to India for 15 days following the second wave of Covid-19.
Pharmexcil fears that the decision of the Chinese airlines would have cascading effects on the entire supply chain, leading to a shortage of essential medicines for not just for India’s domestic needs but also adversely affect its pharmaceutical exports to meet the global needs in the time of the pandemic.
India's overall imports of bulk drugs and drug intermediates amounted to $3.84 billion in fiscal to March 2021. Of this, $2.6 billion or 68% of bulk drugs and intermediates are imported from China.
Uday Bhaskar submitted to the Indian Ambassador Misri that India is currently sourcing 60-70% of its requirement of drug intermediates, key starting material (KSMs) and active pharmaceutical ingredients (APIs) from China. Further, “most importantly 45-50% of all APIs
imported feature in the National List of Essential Medicines (NLEM),” said the Pharmexcil director-general.
Though the Indian government had rolled out the Product Linked Incentive (PLI) scheme for API manufacturing, “it is going to take some time to reduce our dependency on import of KSMs,” said Uday Bhaskar.
The Pharmexcil top executive said even as the Indian pharmaceutical sector was struggling hard to meet the global commitments during the hard phase of Covid second wave, “the decision of Chinese state-owned Sichuan Airlines suspending its cargo services to India for 15 days is worrisome in addition to increased freight cost and shortage of containers.”
Uday Bhaskar said the decision of Chinese Airlines “is likely to disrupt frantic efforts by Indian pharma industry to import medical supplies including oxygen concentrators as well as the KSMs/APIs required to manufacture finished formulations. The Industry is fearing of cascading effects on its entire supply chain leading to a shortage of the essential medicines for the nation’s population as well as severe impact on exports.”
The Pharmexcil director-general appealed to the Indian Ambassador “to intervene and take necessary measures to restore the supply chain of medical needs of our country including KSMs/APIs etc either by restoring the cargo services of Sichuan Airlines or by way of arranging Indian air cargo to lift the medical supplies.”